Atherosclerosis
Volume 148, Issue 1 , Pages 113-124 , January 2000

Coexisting dysbetalipoproteinemia and familial hypercholesterolemia: Clinical and laboratory observations

  • Rafael Carmena

      Affiliations

    • Endocrine Service, Hospital Clinico Universitario, Valencia, Spain
    • ,
  • Madeleine Roy

      Affiliations

    • Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, Quebec H2W 1R7, Canada
    • Corresponding Author InformationCorresponding author. Tel.: +1-514-987-5626; fax: +1-514-987-5700
    • ,
  • Ghislaine Roederer

      Affiliations

    • Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, Quebec H2W 1R7, Canada
    • ,
  • Anne Minnich

      Affiliations

    • Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, Quebec H2W 1R7, Canada
    • ,
  • Jean Davignon

      Affiliations

    • Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, Quebec H2W 1R7, Canada

Received 15 September 1998 ,Revised 30 April 1999 ,Accepted 2 June 1999.

References 

  1. Brewer HB, Zech LA, Gregg RE, Schwartz D, Schaefer EJ. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. Ann. Intern. Med. 1983;98:623–640
  2. Havel RJ. Familial dysbetalipoproteinemia. New aspects of pathogenesis and treatment. Med. Clin. North Am. 1982;66:441–454
  3. Mahley RW, Rall SC. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In:  Scriver CR,  Beaudet AL,  Sly WS,  Valle D editor. The Metabolic and Molecular Bases of Inherited Disease. Seventh edition. New York: McGraw-Hill; 1995;p. 1953–1980
  4. Davignon J. Apolipoprotein E polymorphism and atherosclerosis. In:  Schwartz CJ,  Born GVR editor. New Horizons in Coronary Heart Disease. London: Current Science; 1993;p. 5.1–5.21
  5. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In:  Scriver CR,  Beaudet AL,  Sly WS,  Valle D editor. The Metabolic and Molecular Bases of Inherited Disease. 7th edition. New York: McGraw-Hill; 1995;p. 1981–2030
  6. Moorjani S, Roy M, Gagné C, Davignon J, Brun D, Toussaint M, et al.  Homozygous familial hypercholesterolemia among French Canadians in Québec Province. Arteriosclerosis. 1989;9:211–216
  7. Hobbs HH, Brown MS, Russell DW, Davignon J, Goldstein JL. Deletion in the gene for the low-density lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. N. Engl. J. Med. 1987;317:734–737
  8. Minnich A, Roy M, Chamberland A, Lavigne J, Davignon J. New methods for rapid detection of low-density lipoprotein receptor and apolipoprotein B gene mutations causing familial hypercholesterolemia. Clin. Biochem. 1995;28:277–284
  9. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988;8:1–21
  10. Hopkins PN, Wu LL, Schumacher MC, Emi M, Hegele RM, Hunt SC, et al.  Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2: evidence for a gene–gene interaction. Arterioscler. Thromb. 1991;11:1137–1146
  11. Hazzard WR, Miller N, Albers JJ, Warnick GR, Baron P, Lewis B. Association of isoapolipoprotein E3 deficiency with heterozygous familial hypercholesterolemia: implications for lipoprotein physiology. Lancet. 1981;i:298–301
  12. Nestel PJ, Reardon MF, Fidge NH. Homozygous familial hypercholesterolemia occuring with apoprotein E3 deficiency—report of two cases. Arteriosclerosis. 1984;4:124–129
  13. Sakuma N, Iwata S, Ikeuchi R, Ichikawa T, Hibino T, Kamiya Y, et al.  Coexisting type III hyperlipoproteinemia and familial hypercholesterolemia: a case report. Metabolism. 1995;44:460–465
  14. Ziemer A, Goring HD. Severe type III hyperlipoproteinemia with unusual lipoprotein phenotype in an adolescent patent. Hautarzt. 1993;44:538–544
  15. Feussner G, Dobmeyer J, Nissen H, Hansen TS. Unusual xanthomas in a young patient with heterozygous familial hypercholesterolemia and type III hyperlipoproteinemia. Am. J. Med. Genet. 1996;65:149–154
  16. Morganroth J, Levy RI, Fredrickson DS. The biochemical, clinical and genetic features of type III hyperlipoproteinemia. Ann. Intern. Med. 1975;82:158–174
  17. Lipid Research Clinics Program. Manual of laboratory operations, Vol. 1: Lipid and lipoprotein analysis. US Department of Health, Education and Welfare. Publication no. 75-628 (NIH), Washington, DC. US Government Printing Office 1974;1–81.
  18. Bouthillier D, Sing CF, Davignon J. Apolipoprotein E phenotyping with a single gel method: application to the study of informative matings. J. Lipid Res. 1983;24:1060–1069
  19. Anonymous. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1333–1445.
  20. Ferrières J, Sing CF, Roy M, Davignon J, Lussier-Cacan S. Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia: sex-specific effects. Arterioscler. Thromb. 1994;14:1553–1560
  21. Ferrières J, Lambert J, Lussier-Cacan S, Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation. 1995;92:290–295
  22. Roy M, Sing CF, Betard C, Davignon J. Impact of a common mutation of the LDL receptor gene, in French–Canadian patients with familial hypercholesterolemia, on means, variances and correlations among traits of lipid metabolism. Clin. Genet. 1995;45:59–67
  23. Neter J, Wasserman W, Kutner MH. Regression, analysis of variance and experimental designs. In: Anonymous, editor. Applied Linear Statistical Models, 3rd edition. Homewood IL: RD Irving, 1990.
  24. Anonymous. Santé Québec: Faits saillants de l' enquête québécoise sur la santé cardio-vasculaire 1990. In: Ministère de la Santé et des Services Sociaux, editor. Gouvernement du Québec, 1994:159.
  25. Feussner G, Wagner A, Kohl B, Ziegler R. Clinical features of type III hyperlipoproteinemia: analysis of 64 patients. Clin. Invest. 1993;71:362–366
  26. Schuster H, Kröner KK, Keller C, Spengel F, Wolfram G, Zöllner N. Atherosclerosis of the carotid arteries documented by Duplex Scan as a predictor of coronary artery disease in familial hyperlipidemias. Klin. Wochenschr. 1988;66:65–68
  27. Spengel FA, Kaess B, Keller C, Kröner KK, Schreiber M, Schuster H, et al.  Atherosclerosis of the carotid arteries in young patients with familial hypercholesterolemia. Klin. Wochenschr. 1988;66:65–68
  28. Wendelhag I, Wiklund O, Wikstrand J. Atherosclerotic changes in the femoral and carotid arteries in familial hypercholesterolemia: ultrasonographic assessment of intima-media thickness and plaque occurrence. Arterioscler. Thromb. 1993;13:1404–1411
  29. Dobmeyer J, Lohrmann J, Feussner G. Prevalence and association of atherosclerosis at three different arterial sites in patients with type III hyperlipoproteinemia. Atherosclerosis. 1996;119:89–98
  30. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage. Implications for cholesterol deposition in atherosclerosis. Annu. Rev. Biochem. 1983;52:223–261
  31. Mahley RW. Atherogenic lipoproteins and coronary artery disease: concepts derived from recent advances in cellular and molecular biology. Circulation. 1985;72:943–947
  32. Rapp JH, Lespine A, Hamilton RL, Colyvas N, Chaumeton AH, Tweedie-Hardman J, et al.  Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler. Thromb. 1994;14:1767–1774
  33. Dallongeville J, Roy M, Leboeuf N, Xhignesse M, Davignon J, Lussier-Cacan S. Apolipoprotein E polymorphism association with lipoprotein profile in endogenous hypertriglyceridemia and familial hypercholesterolemia. Arteriosclerosis. 1991;11:272–278
  34. Kotze MJ, De Villiers WJS, Steyn K, Kriek JA, Marais AD, Langenhoven E, et al.  Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler. Thromb. 1993;13:1460–1468
  35. Sass C, Giroux L-M, Ma Y, Roy M, Lavigne J, Lussier-Cacan S, et al.  Evidence for a cholesterol-lowering gene in a French–Canadian kindred with familial hypercholesterolemia. Hum. Genet. 1995;96:21–26
  36. Zhao S-P, Smelt AHM, Van den Maagdenberg AMJM, Van Tol A, Vroom TFFP, Leuven JAG, et al.  Plasma lipoprotein profiles of normocholesterolemic and hypercholesterolemic homozygotes for apolipoprotein E2(Arg158→Cys) compared. Clin. Chem. 1994;40:1559–1566
  37. Lussier-Cacan S, Bard J-M, Boulet L, Nestruck AC, Grothé A-M, Fruchart J-C, et al.  Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III. Atherosclerosis. 1989;78:167–182
  38. Packard CJ, Clegg RJ, Dominiczak MH, Lorimer AR, Shepherd J. Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects. J. Lipid Res. 1986;27:930–938
  39. Zhao S-P, Smelt AHM, Van den Maagdenberg AMJM, Van Tol A, Vroom TFFP, Leuven JAG, et al.  Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158→Cys), E3-Leiden, and E2(Lys146→Gln), and effects of treatment with simvastatin. Arterioscler. Thromb. 1994;14:1705–1716

PII: S0021-9150(99)00212-9

Atherosclerosis
Volume 148, Issue 1 , Pages 113-124 , January 2000

Article Tools